JARDIANCE® provides triple protection in your patients with CRM conditions:
reduced risk of CV death
or kidney disease progression*1,2
reduced risk of CV death
or hospitalisation for heart failure†3,4
reduced risk of CV death‡5
Prof. Christoph Wanner - How do you interpret the results of the primary outcome of EMPA-KIDNEY?
14/03/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-103559